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Abstract  29 
 30 
Clinical studies of new anti-tubercular drugs are costly and time consuming.  Owing 31 
to the extensive TB treatment periods, the ability to identify drug candidates based on 32 
their predicted clinical efficacy is vital to accelerate the pipeline of new therapies.  33 
Recent failures of pre-clinical models in predicting the activity of fluoroquinolones 34 
underlines the importance of developing new and more robust predictive tools that 35 
will optimise the design of future trials.  Here, we have used high-content imaging 36 
screening and pharmacodynamic intracellular modelling (PDi) to identify and 37 
prioritise fluoroquinolones for TB treatment.  In a set of studies designed to validate 38 
this approach, we show moxifloxacin to be the most effective fluoroquinolone, and 39 
PDi modelling-based Monte Carlo simulations accurately predict negative culture 40 
conversion (sputum sterilisation) rates when compared against 8-independent clinical 41 
trials.  Additionally, PDi-based simulations were used to predict the risk of relapse.  42 
Our analyses show that the duration of treatment following culture conversion can be 43 
used to predict relapse rate.  These data further support that PDi-based modelling 44 
offers a much-needed decision making tool for the TB drug development pipeline. 45 
 46 
 47 
Introduction 48 
 49 
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb), is the leading cause 50 
of death from a single infectious agent. The so-called short course treatment of drug-51 
susceptible TB (2-month intensive phase of Rifampicin [RIF], Isoniazid [INH], 52 
Pyrazinamide [PZA] and Ethambutol [EMB] then 4-months of RIF and INH) (1) 53 
remains long, complex and expensive, with relatively high results of failure due to 54 
patient non-compliance and drug resistance.  Fluoroquinolones, were introduced into 55 
the regimen for multi-drug resistant TB (MDR-TB) after demonstration of their in 56 
vitro and in vivo anti-mycobacterial activity (2–6).  They are now considered by the 57 
WHO to be a critical component in MDR-TB treatment.  Fluoroquinolones are also 58 
administered when patients cannot tolerate the standard regimen (7).  However, 59 
fluoroquinolones, especially third generation, are often discussed in terms of a generic 60 
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drug class and the specific choice of fluoroquinolone is generally not specified and is 61 
therefore often based on availability, cost and national guidelines.   62 
 63 
It was anticipated that by introducing fluoroquinolones into drug-susceptible 64 
regimens, the treatment period could be reduced by 2-months (from 6 to 4) (8).  65 
Clinical trials with moxifloxacin (MXF) produced mixed results, with some 66 
displaying superior activity that would indicate shorter treatment courses (9, 10) but 67 
others displaying little, to no acceleration in achieving negative culture conversion 68 
(11, 12).  However, a recent meta-analysis of all clinical data showed a significant 69 
improvement of culture conversion rates in total (13). 70 
 71 
Pharmacokinetic/Pharmacodynamic (PK/PD) models are useful in evaluating the 72 
length of treatment required by new regimens of anti-TB drugs.  Recent clinical trials 73 
have highlighted the concerns of preclinical studies.  Animal models show dynamics 74 
that differ to those observed in humans (14, 15) and predicted treatment 75 
improvements observed in mice with reformed regimens have often failed to reflect 76 
similar results in clinical settings.  For example, murine studies with rifamycins (16–77 
18) over-predicted the superior activity of higher doses of rifapentine in clinical 78 
studies.  Similarly, animal studies were interpreted as showing a significant potential 79 
for the reduction in time of TB treatment with MXF, (19) suggesting that treatment 80 
could be reduced by 1-month based on the in vivo results (20).  However, phase 3 81 
clinical trials (e.g. REMOX and RIFAQUIN) highlighted that despite the superiority 82 
of MXF, it was insufficient to display relapse-free cure rates observed in 6-months of 83 
conventional TB therapy (11, 21). 84 
 85 
We have previously shown that PD data obtained from an in vitro intracellular 86 
(macrophage) Mtb high-content imaging-based platform, termed intracellular 87 
pharmacodynamics (PDi), can be a powerful tool for predicting the activity of first 88 
line TB drugs in patients (22).  Our platform is capable of defining the killing kinetics 89 
of first line anti-TB drugs against intracellular Mtb.  Building from this previous 90 
work, and using a refined method that allows for extended monitoring of live drug-91 
exposed intracellular Mtb, here we profile fluoroquinolones to assess their anti-92 
tubercular efficacy.  In addition, using this data we have performed PDi -based 93 
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PK/PD predictions of clinical outcome in terms of culture conversion rates and 94 
compare these values with clinical studies.  Data is discussed in the context of the use 95 
of fluoroquinolones towards shortening treatment duration and the value of the PDi -96 
based approach as a decision-making tool in the drug development of new treatment 97 
therapies. 98 
 99 
 100 
Results  101 
 102 
Fluoroquinolones exhibit comparable rates of kill against intracellular Mtb, but 103 
differ in potency 104 
The efficacy of selected fluoroquinoles against intracellular Mtb was initially 105 
determined using the described fluorimetric-based assay (see methods).  The 106 
intracellular anti-tubercular activity of MXF, levofloxacin (LVX), norfloxacin 107 
(NOX), ofloxacin (OFX), sparfloxacin (SPX), and ciprofloxacin (CIP) was assessed 108 
at a concentration range between 0.01 mg/L – 100 mg/L.  The kill rate elicited by 109 
each concentration was then calculated as previously described (22).  Figure 1 110 
displays the kill rate for each drug’s concentration range.  A concentration-effect 111 
relationship using a three-parameter pharmacological model was then determined for 112 
each drug (Fig. 2).  This model affords the calculation of pharmacological parameters, 113 
namely EC50 and maximal kill rates for each drug (Fig. 2 a-f).  Figure 2 (g) compares 114 
the profiles of all drugs where the grey area represents the kill rate of RIF (first-line 115 
antibiotic) at 25 mg/L (chosen as it is 1000 fold the EC50 concentration and is used to 116 
determine the Emax, see Methods).  117 
 118 
The fluoroquinolones tested displayed variability in potency for their respective 119 
intracellular anti-TB activity.  SPX displayed the lowest EC50 (0.051 mg/L), followed 120 
by MXF, CIP and LVX (0.238 mg/L, 0.259 mg/L and 0.382 mg/L respectively) 121 
whilst OFX and NOX displayed poor activity with EC50 levels of 1.414 mg/L-1.705 122 
mg/L as shown in Figures 1-2 and Table S1.  Of note, although fluoroquinolones 123 
displayed variation in EC50 values, the maximal kill rate for all fluoroquinolones was 124 
determined to be comparable (Fig. 2g) – consistent with the drugs possessing the 125 
same mode of action. 126 
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 127 
Similar to our previous work with RIF, INH and EMB (22) , MXF kill rate of Mtb 128 
grown in culture, termed extracellular, was significantly faster than the kill rate of 129 
MXF against intracellular (macrophage) Mtb (0.23 h
-1
 extracellular Vs. 0.055 130 
intracellular, Fig. S1, and Fig. 1, respectfully)  131 
 132 
 133 
Determination of the Mtb growth-kill rate ratio for fluoroquinolones 134 
 135 
The above described live Mtb fluorimetry-based assay allowed for rapid 136 
determination of kill rate EC50 for the described fluoroquinolones, using a population-137 
based fluorometric readout of intracellular Mtb.  To define the maximal killing rate 138 
for the fluoroquinolone class at greater resolution and dynamic range, killing 139 
dynamics were measured using the Operetta-based high content imaging screen, 140 
which can image individual bacilli residing inside macrophages (Fig. 3).   141 
 142 
Figure 3 displays intracellular Mtb in the absence (a) or presence of MXF (b) (63 x 143 
magnification), (c) shows the maximal kill rate displayed by MXF (100 mg/L) 144 
compared to RIF at a concentration of 25 mg/L.  The maximal kill rate of both drugs 145 
was equivalent and measured approximately -1.8 × no drug control growth rate.  This 146 
concurs with the maximal ‘kill: growth’ ratio previously reported for RIF (22).  Our 147 
results demonstrate that despite RIF being the superior compound, by way of a lower 148 
EC50 value (0.019 mg/L RIF Vs. 0.238 mg/L MXF), the kill rate : growth rate ratio of 149 
MXF at a maximal concentration (100 mg/L) was 1.82 – similar to that of RIF at a 150 
maximal concentration (Fig. 3 & Fig. S2and Fig. S3).  151 
 152 
 153 
PDi modelling predicts culture conversion rates when compared with clinical 154 
trial data  155 
 156 
MXF data from the Operetta based high content imaging screen was modelled and 157 
compared to clinical trial data reported in the literature.  PDi modelling was 158 
performed for MXF using PD data obtained from the Operetta study.  PK data and 159 
pulmonary exposure were calculated for MXF as reported when administered 160 
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concomitantly with RIF as all simulations assumed concomitant administration of the 161 
two drugs (23, 24). Epithelial lining fluid (ELF) concentrations were used as a 162 
surrogate for pulmonary exposure and were obtained from the literature as estimated 163 
in healthy volunteers (25, 26).  In the absence of such ratios in TB patients, we used 164 
healthy volunteer data as the closest possible estimate.  165 
 166 
PDi modelling was used to generate COX regression curves.  The curves indicate 167 
percentage of patients achieving culture-negative conversion over time (culture 168 
conversion to negative is defined as <10 CFU/mL in sputum tests) (27).  169 
 170 
To compare our predictions with the clinical literature, we used Monte Carlo 171 
simulations to generate hypothetical treatment outcomes when using the same 172 
regimens previously used in clinical trials.  PDi modelling predicted that within 8-173 
weeks, 96% of patients would achieve culture-negative status when INH or ETB is 174 
replaced with 400 mg MXF (PK/PD properties of partner drugs were based on (22) as 175 
shown in Table S1).  Our results concur with several clinical studies, as displayed in 176 
Table S2 and Figure 4.  PDi based odds ratios were estimated to be 1.726 (CI: 1.216-177 
2.45) which compares with reported or calculated ratios from clinical literature data 178 
(Table S2, Fig. 4).  PDi prediction of culture conversion rates for MXF containing 179 
regimens seems to be marginally faster than that observed in the most comprehensive 180 
study (11).  However, our prediction is in line with the median of 8 different clinical 181 
studies over 8 weeks (Fig. 4b and Table S2).  182 
  183 
Table S3 displays the sensitivity analysis of the PDi modelling (see Methods), which 184 
indicates that the maximal kill rate (Emax) of MXF is the most influential parameter 185 
upon bacillary clearance.  The second most significant parameter is the initial 186 
intracellular burden the patient presents at the clinic, concurring with previous clinical 187 
studies (28, 29), followed by the PK parameters and MXF drug potency (EC50).  188 
Potency and PK parameters of RIF ranked lower than MXF parameters in our 189 
sensitivity analysis. Parameters for other partner drugs (INH, EMB or PZA) played a 190 
negligible role in the overall outcome of the simulations.     191 
 192 
 193 
 194 
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 195 
Higher concentrations of LVX is predicted to be as effective as MXF at killing 196 
Mtb 197 
 198 
As the PDi model is ultimately based on pulmonary exposure (i.e. concentration in 199 
ELF) we compared the overall PK properties and the ELF exposures of MXF, CIP 200 
and LVX (Table S4).  Simulations predict MXF to have superior PK properties due to 201 
its relatively high AUC level in the plasma, and it displays the highest accumulation 202 
in the ELF.  Table S4 shows that LVX at a higher dose of 750 mg/day would achieve 203 
a very similar pulmonary PK profile to that observed for MXF at 400 mg/day. 204 
Assuming linear PK for LVX, 500 mg/day is expected to achieve inferior ELF 205 
exposure to 400 mg/day of MXF.  At 1000 mg dose, LVX has a comparable ELF 206 
AUC value (221.7 mg.h/L) compared to a standard dose of MXF of 400 mg/day 207 
(173.1 mg.h/L).  Systematic PK parameters were chosen from previously reported 208 
data as per Table S4.   209 
 210 
Simulating various doses of LVX and MXF and integrating this with our imaging-211 
based PDi data, reveals that an increase of LVX from 500 mg to 1000 mg results in a 212 
remarkable improvement in activity (88% of patients predicted to achieve negative 213 
culture conversion at 8 weeks with 500 mg LVX Vs. 93% of patients predicted to 214 
achieve negative culture conversion at 8 weeks with 1000 mg LVX, Fig. 5).  In 215 
contrast, we predict that an increase in the dose of MXF from 400 mg to 800 mg 216 
would result in a more modest improvement (95% of patients to achieve culture 217 
negative status with 400 mg MXF Vs. 96% with MXF 800 mg) (Fig. 5).  218 
 219 
Using PDi -based modelling to predict TB treatment duration and risk of relapse 220 
 221 
As described, fluoroquinolones have been clinically assessed in efforts to shorten 222 
standard therapy (7, 20, 30).  We believe culture conversion is related to relapse rates 223 
and hypothesise that following culture conversion, further therapy is required to kill 224 
hidden/recalcitrant bacilli populations. Figure 6 displays how many patients would 225 
hypothetically be at risk of disease relapse when comparing the standard regimen to a 226 
MXF arm for 4 or 5-months.  We hypothesise that this is directly related to the time 227 
taken to culture convert during treatment, which will differ between all patients.  As 228 
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shown, 6% of patients in the standard treatment arm will culture convert late (<80 229 
days before end of treatment), and therefore not receive treatment for 80 days post 230 
conversion, compared to 15% in the 4-month MXF and 4% in the 5-month MXF arm.  231 
Discussion  232 
 233 
PDi modelling has previously been utilised for the prediction of treatment outcome 234 
for TB patients receiving standard or high dose RIF therapy (22, 31)  Herein, we have 235 
used a similar approach to predict treatment outcomes using fluoroquinolone-based 236 
regimens.  Fluoroquinolones have been considered by many to be a means of 237 
shortening the current standard therapy (7, 20, 30). 238 
 239 
We have presented intracellular killing kinetics for 6 different fluoroquinolone drugs 240 
assessed using two methods.  The first method is useful for rapid ranking of the 241 
potency of the various drugs resulting in concentration-effect relationships (Table S1).  242 
This allows for the identification of the best candidates for further analysis.  The 243 
results demonstrated that 4 out of the 6 fluoroquinolones have similar potencies 244 
(MXF, LVX, CIP, SPX).  Despite RIF, our control compound, being superior overall, 245 
MXF displayed a similar maximal kill rate in both the live fluorimetry and the fixed 246 
Operetta assay.  Yet, patients treated with a 4-month regimen containing MXF 247 
showed higher rates of disease relapse despite achieving faster culture conversion in 248 
comparison to standard treatments (11). MXF however, has superior PK properties 249 
compared to a standard regimen of RIF (which is currently dosed sub-optimally), 250 
especially in its accumulation in the lung and ELF.  The high accumulation levels 251 
compensate for the lower potency when compared to RIF and leads to better overall 252 
effect in Monte Carlo simulations, predicting a median culture conversion time of 31 253 
days compared to 56 days for standard treatment.    254 
 255 
Our intracellular data was in agreement with data from a murine macrophage study, 256 
showing that NOX and OXF are significantly less potent than MXF (32).  Whilst SPX 257 
displayed the lowest EC50, cytotoxicity was observed as reported in the literature (33) 258 
therefore it was eliminated from further investigation.  MXF, CIP and LVX showed 259 
similar potency and maximal kill rates.  CIP displayed a similar EC50 to MXF in our 260 
study but at 500 mg it has 10-fold lower exposure in the ELF when compared to MXF 261 
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at 400 mg (25).  Therefore, only MXF and LVX were considered further in our 262 
analyses.  A 1000 mg dose of LVX has a comparable ELF AUC value (221.7 mg.h/L) 263 
compared to a standard dose of MXF of 400 mg/day (173.1 mg.h/L, Table S4) and 264 
that at this higher dose, the clinical efficacy of LVX, in terms of culture conversion 265 
rates, is predicted by the PDi-based modelling to be comparable to MXF (Fig. 5).  266 
This observation is consistent with a recent clinical study comparing MXF (400 mg) 267 
to high dose (750 mg) LVX, demonstrating that both regimens results in a similar 268 
clinical outcome (34, 35).  These data support that, in the absence of any safety 269 
concerns, LVX should be further trialed at higher doses. 270 
 271 
Similar to the work described previously (22), we show that it is the intracellular kill 272 
rate of MXF that limits the reduction of CFU burden, even when the intracellular 273 
population represents just 5% of the overall population (with in our model 95% 274 
represented by extracellular Mtb). Supplementary figure 4 displays the biexponential 275 
nature of CFU reduction which, in our simulation, is a direct result of having two 276 
separate populations (extracellular and intracellular) (Fig. S4).   277 
 278 
That our PDi-based modelling approach (using short-term measurements of 279 
intracellular Mtb killing) is able to predict long-term clinical responses, is perhaps not 280 
surprising when it is considered that the majority of patients (ca. 80 %) culture 281 
convert within ca. 8 weeks of treatment (36).  We have previously shown that clinical 282 
biphasic treatment responses can be explained by an initial reduction in extracellular 283 
Mtb followed by a second slower phase of bacillary clearance that largely corresponds 284 
to the killing dynamics of intracellular (macrophage) Mtb (22, 37).  The duration of 285 
this second slower bacillary clearance rate is typically 5-6 weeks.  Therefore, the PDi-286 
based modelling approach should be viewed as a predictive tool to determine the 287 
clinical response over this shorter time-frame, which is nonetheless a critical clinical 288 
feature to assess drug efficacy.  Clearly, the PDi-based modelling approach does not 289 
take into account the response to treatment of slow growing/dormant bacilli, which 290 
are thought to be relevant to TB treatment outcome (38).  However, given the strong 291 
agreement in the PDi-based modelling to observed clinical bacillary clearance 292 
responses, it is our view that these important PD and PK considerations are more 293 
relevant in terms of predicting microbiological treatment outcomes and potentially 294 
treatment relapse rates.   As described, this study proposes that a useful proxy to 295 
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estimating disease relapse is the treatment duration post culture conversion, and 296 
therefore knowledge of bacillary clearance rates for drugs and drug combinations can 297 
be used to inform treatment outcome and relapse rates. 298 
Should MXF be introduced to the standard treatment? 299 
 300 
Incorporating MXF into treatment regimens results in faster clearance rates of bacilli 301 
compared to standard treatment in 8 different clinical studies (39).  As 302 
aforementioned, Gillespie et al. 2014 showed that a 4-month MXF based treatment 303 
results in a higher relapse rate (11, 21).  Superior culture conversion results indicate 304 
that relapse rates should be lower in the MXF arm.  PDi simulations can accurately 305 
predict the percentage of patients reaching culture-negative status when compared to 306 
observed clinical findings (Table S2).  Additionally, sensitivity analysis (Table S3) 307 
indicates that MXF in these regimens is the main driver of activity in combination 308 
treatments and its effect significantly supersedes that of RIF, thus explaining the 309 
accelerated clearance of bacilli when MXF is introduced to the drug regimen. 310 
 311 
However, the culture conversion rates in clinical findings did not predict the high 312 
relapse rate in the MXF arm that was reported in Gillespie et al. 2014.  One 313 
explanation of this disparity between bacilli clearance rates and disease relapse could 314 
be related to length of time treatment is received after achieving negative culture 315 
conversion.  This will vary between individual patients. We hypothesise that each 316 
patient requires treatment exceeding 80-days following culture conversion.  For 317 
example, according to our PDi predictions, in the 4-month MXF arm 12% - 17% of 318 
patients will be at risk of relapse as they will culture convert late and receive 319 
treatment for less than 80-days after culture converting (Fig. 6).  In contrast, only 7% 320 
will be at risk of relapse in the standard 6-month arm.  The remaining 93% will 321 
remain on treatment for more than 80-days after culture conversion.  We have 322 
suggested an 80-day duration post culture conversion, because this is the duration that 323 
predicts 15% relapse rate which agrees with relapse rates observed in the Gillespie et 324 
al. 2014 clinical trial with MXF containing regimens. This correlation between 325 
delayed culture conversion and relapse rate has previously been suggested (40) 326 
although this seems to be with limitations as many patients with delayed culture 327 
conversion might still have favourable outcomes.  Based on our data and simulations, 328 
introducing MXF into the standard regimen could lead to a reduced treatment period 329 
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e.g. from 6 to 5-months. These findings further support the notion of individualised 330 
therapy, where patients with late culture conversion could receive treatment for longer 331 
durations than those with early culture conversion (41). 332 
 333 
Conclusions 334 
 335 
Our preclinical model may offer an insight into the performance of compounds with 336 
the overall aim of reducing the TB treatment period down from 6-months.  By adding 337 
MXF into the regimen, we predicted the treatment outcome and could offer 338 
recommendations for its use in the clinic.  Although results from previous clinical 339 
trials were disappointing when substituting MXF into the standard regimen, it is a 340 
well-tolerated compound with high anti-mycobacterial and favourable ELF properties.  341 
Based on our modelling, MXF and LVX have the potential to shorten the treatment 342 
period and our data aligns with independent clinical results.  The individual timeframe 343 
for which a patient converts to a culture-negative status is particularly important when 344 
determining treatment duration, and a more individual based therapy would be highly 345 
beneficial in reducing treatment duration and potentially in reducing relapse rates.  346 
 347 
 348 
 349 
Materials and Methods 350 
 351 
Chemical Compounds 352 
 353 
The fluoroquinolones moxifloxacin (MXF), levofloxacin (LVX), norofloxacin 354 
(NOX), ofloxacin (OFX), sparfloxacin (SPX), and ciprofloxacin (CIP) were 355 
purchased from Sigma, UK.  All compounds were made up in DMSO (Sigma).  356 
 357 
Mycobacterial Strain, Growth and Macrophage Growth 358 
 359 
Mtb H37Rv expressing the far-red reporter mCherry, was used in this study (H37Rv-360 
mCherry) (22).  Aliquots of H37Rv-mCherry was pre-cultured aerobically at 37°C in 361 
Middlebrook 7H9 broth (Difco) supplemented with 0.05% (v/v) Tween 80 (Sigma), 362 
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0.2% (v/v) glycerol, 10% oleic acid-albumin-dextrose-catalase (OADC) (7H9) and 50 363 
mg/L hygromycin (Sigma) with magnetic stirrers.  THP-1 cells were routinely 364 
cultured in RPMI 1640 supplemented with L-Glutamine, NaHCO3 (Gibco) and 10% 365 
heat-inactivated fetal bovine serum (HI-FBS; Gibco), at 37˚C, 5% CO2.   366 
Macrophage Infection Assay  367 
 368 
THP-1 cells were differentiated in PerkinElmer
®
 CellCarrier-96 plates, seeded at 5 × 369 
10
5
 cells per well and differentiated for 72 h in supplemented RPMI 1640 and 100 370 
ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma) at 37˚C, 5% CO2.   371 
Differentiated THP-1 cells were infected with H37Rv-mCherry in suspension at a 372 
multiplicity of infection (MOI) of 1:5 in FluoroBrite™ DMEM supplemented with 373 
10% HI-FBS and L-Glutamine for 24 h at 37°C.  For optimal macrophage 374 
environment, each 96 well plate was covered with a Breath-EASIER
TM
 sealing 375 
membrane (Sigma) to allow gaseous exchange but maintaining containment level 3 376 
safety regulations.  This has been refined from our previous work, improving the 377 
THP-1 cell growth conditions.  After 24 h the cells were washed, the drugs at required 378 
concentrations were added in FluoroBrite™ DMEM+ to a total volume of 200 µL.  379 
Infected cells were incubated for up to 144 h.    380 
 381 
Extracellular-grown (planktonic) Mtb kill kinetics were obtained by incubating Mtb 382 
H37Rv in the presence of test drug followed by plating to obtain colony forming units 383 
(CFUs).  Mtb was cultured at 37°C in Middlebrook 7H9 broth (Difco) supplemented 384 
with 0.05% (v/v) Tween 80 (Sigma), 0.2% (v/v) glycerol, 10% oleic acid-albumin-385 
dextrose-catalase (OADC) (7H9) and 50 mg/L hygromycin (Sigma) with magnetic 386 
stirrers, to the mid-log growth phase before two-fold dilutions of test drug ranging 387 
from 15360 to 30 ng/mL were added.  A sample of culture was plated at 0 h before 388 
drug was added to obtain the initial bacterial count.  After the addition of drug, 2 mL 389 
aliquots of bacterial culture with magnetic stirrers were incubated at 37°C in complete 390 
media. At defined time intervals of 24, 48, 72, 96, and 168 h, aliquots were pelleted to 391 
remove drug.  These were serially diluted in PBS, plated on Middlebrook 7H11 agar 392 
and incubated at 37°C in 5% CO2 for 28 days.  The Miles Misra method was used to 393 
determine CFUs (42). 394 
 395 
 396 
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 397 
 398 
Fluorometer Drug Screening, High-content Image Acquisition and Data Analysis 399 
 400 
Data were generated from multiple independent experiments (n ≥ 3) all performed at 401 
least in triplicate and data were produced via two methods.  First, each plate was 402 
screened every 24 h for fluorescence using a Varioskan (LUX
TM
 multimode reader, 403 
Thermo Scientific
TM
) at an excitation (ex) of 578 nm and emission (em) of 610 nm 404 
thus producing ‘live’ fluorometer readouts.  Additionally, plates were fixed with 5% 405 
paraformaldehyde (PFA) (Sigma) for 2 h for imaging using an Operetta 406 
(PerkinElmer
®
) with a 60x High NA objective as described previously (22). 407 
 408 
The Z′-factor for the Varioskan assay was calculated according to equation 1 as 409 
reported in Zhang et al. 1999 (43) and calculated to be 0.57 for the data set. 410 
 411 
 412 
Unlike the Operetta-based high content imaging screen, maximum kill rates cannot be 413 
calculated from the fluorometer.  Upon bacilli death, the measured linear response of 414 
Mtb to a compound eventually plateaus limiting the dynamic range of the assay.  415 
 416 
 417 
Data Analysis and Modelling  418 
 419 
Fluoroquinolone activity was ranked using the Varioskan fluorimeter readout.  An 420 
algorithm was used for drug combinations where the overall kill rate at any given 421 
time is equal to the kill rate of the drug with the highest kill rate at that given time 422 
point (this kill rate is dependent on the changing of a drug’s concentration and its 423 
constant PD parameters [EC50 and Emax]). Hence, the model assumes that there are no 424 
positive or negative PD interactions between the drugs (31).  Bacterial growth and 425 
death rates at differing drug concentrations were measured using Pmetrics GraphPad 426 
Prism
®
 per the following equation: 427 
 428 
𝑀𝑡𝑏 𝑐𝑜𝑢𝑛𝑡 = 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝑡𝑏 𝑐𝑜𝑢𝑛𝑡 ∙  (1 − 𝑒𝑥𝑝(−𝐾 ∗ 𝑥))…… eq.2 429 
 430 
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Where K represents the growth rate per hour and would be a negative value if the 431 
bacterial count is decreasing over time.  Each drug concentration generated an 432 
independent K value.  This value was normalised to bacterial growth per experiment 433 
to avoid inter-experimental bias and thus the growth rate was divided by the K value 434 
to normalise the kill rate.  Kill rates at different concentrations are then fitted to a 3-435 
parameter pharmacological model per the following equation using Graphpad Prism
®
: 436 
 437 
𝐸 =  
𝐸𝑚𝑎𝑥∙𝐶
𝐸𝐶50+𝐶
+ 𝐸𝑚𝑖𝑛 …… eq.3 438 
 439 
Where E is the kill rate at any given concentration, Emax is the maximal kill rate of 440 
each drug, C is the drug concentration in mg/L and EC50 is concentration required to 441 
achieve half the maximal kill rate.  442 
 443 
Extracellular-grown Mtb kill rates and EC50 values for RIF, INH and EMB, were 444 
derived from our previous study (22), while MXF extracellular EC50 (356 ng/mL) and 445 
kill rate (0.23h
-1
) were derived in this study (Fig. S5). LVX extracellular Emax and 446 
EC50 were assumed to be similar to MXF for the purposes of this work.  447 
 448 
 449 
Modelling parameters  450 
 451 
Parameters for RIF, INH, PZA and EMB were derived from our previous work (22), 452 
whereas parameters for fluoroquinolone drugs were derived from experiments 453 
described herein.  Supplementary Table 5 summarises the parameters used for the 454 
simulation with the corresponding references. 455 
 456 
We observed a very strong correlation between the growth rate and the corresponding 457 
kill rate in all experiments for all drugs screened.  RIF and MXF exhibited similar 458 
maximal kill rates that always varied between 1.6-2-fold higher than the growth rate, 459 
regardless if the latter was fast or slow.  The consistency in the ratio between the 460 
growth and kill rates allows the ability to correct all data to a fixed growth rate, in all 461 
simulations, to reduce output noise whilst not compromising the final outcomes.  462 
Reported intracellular Mtb growth rates (also known as doubling times, DT), 463 
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including those reported by us, range from DT 21 h to DT 48 h, (22, 44, 45) whilst in 464 
vivo rodent TB models report an intracellular DT for Mtb close to 25 h (46). The 465 
reason for the reported variation is not fully understood, but could be partially 466 
explained by macrophage modulation of M0/M1/M2 polarisation (37).  For the 467 
described PDi-based modelling approach, we chose a DT of 21 h for consistency with 468 
previous studies and to avoid bias in cross-study comparisons in the future. 469 
 470 
 471 
Monte Carlo Simulations 472 
 473 
Monte Carlo simulations for PK/PD predictions were performed using Pmetrics
®
 with 474 
PK parameters derived from the literature.  PK values for MXF were chosen from 475 
studies where MXF was administered with RIF, due to the known PK interaction 476 
between the two drugs (23, 24).  PK for other standard drugs were used as previously 477 
described (22).
 
478 
 
479 
The models utilised for Monte Carlo simulations herein were previously described in 480 
detail in (22, 31).  Briefly, the CFU reduction in each simulated patient was driven by 481 
exposure to drug and kill rate of each drug according to an Emax model (Eq. 3). 482 
Extracellular and intracellular bacilli respond differently to drug treatment and both 483 
reservoirs were simultaneously simulated for each patient, resulting in a biexponential 484 
decrease in total CFU burden over time (Fig. S3). Overall drug kill rate (of all drugs 485 
in combination) is equal to the rate of the fastest acting drug at the same time.  This is 486 
determined by the epithelial lining fluid (ELF) drug exposure and its intrinsic rate of 487 
kill (as defined in vitro) at any given time point for each drug. 488 
 489 
Initial clinical colony-forming unit (CFU) count in each of the 1000 simulated 490 
patients’ lungs was assumed to be 107 CFU/mL (22).   All PK profiles for analysis 491 
were assumed to follow a 1-compartment model.  Pulmonary levels of drug which 492 
were assumed to be the driver for activity (where C in equation 2 represents drug 493 
concentration in the ELF); ELF levels were estimated by using ELF:Serum ratio 494 
reported in the literature as previously described for RIF, ETB, INH and PZA and an 495 
ELF ratio of 5.2 was estimated for MXF (47).  The CFU change was recorded over 496 
time at fixed intervals of 1 week over a simulated run time of 4-months 497 
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(MXF+RIF+INH+PZA) containing regimens) to 6-months (standard regimen).  It was 498 
assumed that a 10 CFU/mL or lower outcome at any given time would indicate 499 
culture conversion to be negative, as previously described (22).  The number of 500 
patients converting to culture negative status in the simulation every week was then 501 
recorded for further survival analysis.  Supplementary Table 5 summarises the 502 
parameters used for the simulation with the corresponding references.  503 
 504 
Odds ratios were calculated using IBM
®
 SPSS
®
 Statistics Version 24 (property of 505 
IBM Corp). Data generated form Monte Carlo simulation from different scenarios 506 
were compared head to head and the odds ratio with 95CI was estimated accordingly.  507 
 508 
Sensitivity analysis was performed to assess the most influential parameters upon the 509 
bacillary clearance within the simulation (Table S3). The analyses were performed 510 
using the FME package (A Flexible Modelling Environment for Inverse Modelling, 511 
Sensitivity, Identifiability and Monte Carlo Analysis) with R version 3.4.2 (48).  512 
Influence of each parameter was expressed in terms of L1-norm and L2-norm 513 
measures which rank parameters by their effect upon the simulation.  The higher the 514 
L1-norm or L2-norm for a given parameter, the higher the sensitivity (49).  Sensitivity 515 
analysis (Table S3) shows that MXF would be the main driver of activity in a 516 
combination of drugs. This is further corroborated by observing the changing kill rate 517 
over time for each of the partner drugs which shows that MXF dominates as the 518 
fastest killer throughout the treatment duration, followed by RIF while INH and PZA 519 
play a negligible role in the overall clearance of bacilli (Fig. S5). 520 
 521 
 522 
Methodological assumptions and limitations 523 
 524 
Whilst fluorimetric-based measurements of intracellular Mtb can effectively measure 525 
bacillary growth, this approach has a limited dynamic range when assessing bacillary 526 
sterilisation over time when measurements fall below the minimum limit of 527 
fluorescence detection.  To overcome this issue, high-content (Operetta) imaging was 528 
used to more accurately measure time-dependent bacillary sterilisation for specific 529 
drugs.  With regards to intracellular Mtb growth, during the course of this and our 530 
other studies, as well as in studies by other laboratories, we noted a variation in 531 
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intracellular Mtb DT, as aforementioned in the ‘Modelling Parameters’ section.  To 532 
normalise for this in our mathematical modelling, we selected a DT of 21 h 533 
throughout.  Furthermore, for the purpose of the mathematical modelling/simulations 534 
to predict clinical outcome, in the absence of evidence to the contrary, we also made a 535 
number of assumptions, including; (i) it was assumed that there is no pharmacological 536 
interaction [synergy/additivity/antagonism] between the modelled drugs, therefore the 537 
clinically observed Mtb sterilisation rate was equivalent to the sterilisation rate of the 538 
drug with the fastest sterilisation rate.  It was also hypothesised that (ii) PD 539 
interactions of drugs against intracellular (macrophage) Mtb measured in in vitro 540 
culture were similar to those in the ELF.  541 
 542 
It should be noted that whilst time-dependent intracellular Mtb sterilisation rates and 543 
PDi -PK modelling have been used in this study to predict the clinical activity of 544 
fluoroquinolones against TB, this approach generates dynamic parameters (e.g. EC50 545 
and Emax) that are not suitable for comparison with traditional static microbiological 546 
parameters such as MIC. 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
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Figures and Tables 802 
 803 
Fig. 1.  Intracellular (macrophage) Mtb time-dependent kill profiles of fluoroquinolones.  Panels 804 
display time-kill profiles of (a) MXF, (b) CIP, (c) SPX, (d) LVX, (e) OFX, and (f) NOX.  Mtb control 805 
(no drug) in black and RIF at 25 mg/L in red.  Data is mean ± S.D derived from multiple independent 806 
experiments (n ≥ 3) performed at least in triplicate. 807 
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 808 
Fig. 2. Concentration-intracellular Mtb kill rate relationship for selected fluoroquinolones 809 
 Open black circles represent individual kill rates at each concentration for drugs and the dashed black 810 
line displays the 3-parameter pharmacological fit for each drug (a) MXF, (b) CIP, (c) SPX, (d) LVX, 811 
(e) OFX, (f) NOX.  (g) Represents a comparison of the profiles of all drugs - grey area represents the 812 
kill rate of RIF at 25 mg/L.  n=6 in 3 independent experimental replicates for each drug. 813 
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 814 
 815 
 816 
 817 
 818 
     819 
 820 
 821 
 822 
Fig.3. High-content fluorescent images as acquired from the Operetta (PerkinElmer) 823 
Fixed macrophages infected with Mtb H37Rv expressing the far-red reporter mCherry after 72 h with 824 
(a) no drug treatment or (b) with 100 mg/L MXF.  H37Rv-mCherry (orange), macrophage nuclei 825 
stained with Hoechst (blue), scale bar 50 m, (c) represents activity of MXF against intracellular Mtb 826 
(data acquired from the Operetta via Harmony, PerkinElmer) with the red solid line displaying the 827 
maximal kill rate obtained by RIF at 25 mg/L. 828 
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 833 
 834 
a) 835 
 836 
  b) 837 
 838 
Fig. 4. Culture conversion rates and forest plot of odds ratios 839 
(a) Observed culture conversion rates from patients treated with MXF+RIF+EMB+PZA for 4-months 840 
in a clinical study by Gillespie et al. 2014 (solid black line) compared to our PDi prediction for the 841 
same dosing regimen over the same duration (dashed blue line). (b) Forest plot showing odds ratios 842 
from 8 clinical studies (39) compared to odds ratio calculated using our PDi based Monte Carlo 843 
simulations. Grey area represents range of PDi prediction. 844 
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 845 
 846 
 847 
 848 
Fig. 5. PDi predictions 849 
PDi prediction of culture conversion rates for MXF (400 mg daily, 4-months, dashed blue line) Vs. 850 
LVX (1000 mg daily, 4-months, solid black line), LVX (500 mg daily, 4-months, dashed red line) and 851 
MXF (800 mg daily, dashed green line). 852 
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 861 
 862 
 863 
 864 
Fig. 6.  Predicted or observed relapse rates  865 
The % of patients that are predicted to relapse (based on late culture conversion status) (black bars) 866 
compared to observed relapse rates as observed in Gillespie et al. 2014 (grey bars).  The observed 867 
relapse rates are based on both MXF arms in the clinical study. * 5 month MXF data not available.  868 
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